Thierry Andre, MD

Thierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique H&ocirc;pitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer (mCRC).

In CheckMate-142, an immunotherapy combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was tested in a small subset of patients with mCRC. According to Andre, the study looked at patients with

microsatellite instability-highmCRC with a primary objective of overall response. There was a 55% response rate in this patient population, with the combination demonstrating a low toxicity profile that was only slightly higher than what is found with monotherapy. Also, toxicity-related discontinuation occurred in just a small number of patients, around 15%.

Andre notes this trial was not randomized and the combination was only tested in a small population of patients. This particular subset of patients only makes up about 4% of the CRC population. However, Andre says this is only the beginning of immunotherapy in this setting.

Videos

Thierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique H&amp;ocirc;pitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer.

Moving Forward With Results From CheckMate-142 in MSI-H mCRC

Thierry Andre, MD, a professor of medical oncology at the University Pierre et Marie Curie, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique H&ocirc;pitaux de Paris, discusses factors that a community oncologist should consider when choosing the right treatment for patients with metastatic colorectal cancer.

To date, the best way to treat patients with colorectal or metastatic colorectal cancer is with radiation. This is the standard of care for all gastric cancers at the St. Antoine Hospital in Paris, Andre explains.

Despite the success in the field of immunotherapies, every patient needs to be looked at individually before coming up with a treatment regimen. Immunotherapies should only be used on patients that can expect to benefit from this treatment.

Thierry Andre, MD | Authors

Articles

Moving Forward With Results From CheckMate-142 in MSI-H mCRC

Using Immunotherapy for the Treatment of mCRC